Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide for autistic children with known etiology
2016-000106-11Phase 2Completed
- Sponsor
- CHU de Limoges
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Bumetanide with Placebo (2 arms). Primary endpoint: Change in CARS score from day 0 to day 99. Started Oct 2016; status: completed.
02
Drugs
bumetanide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2016-000106-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000106-11.